Content about Adrenal gland disorders

May 1, 2013
Prasco to distribute authorized generic treatment for tumor disorder

Prasco Labs has signed a deal with WellSpring Pharmaceutical Corp. to market an authorized generic version of a drug for a rare tumor disorder.

CINCINNATI — Prasco Labs has signed a deal with WellSpring Pharmaceutical Corp. to market an authorized generic version of a drug for a rare tumor disorder.

The company announced Wednesday the distribution and supply agreement for phenoxybenzamine hydrochloride capsules in the 10 mg strength for pheochromocytoma, an adrenal gland tumor disorder. The drug is used to control episodes of hypertension and sweating associated with the disorder.

December 17, 2012
FDA approves Novartis drug for Cushing's disease

The Food and Drug Administration has approved a new drug to treat a rare but serious endocrine disorder.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a new drug to treat a rare but serious endocrine disorder.

Swiss drug maker Novartis announced the approval of Signifor (pasireotide), an injectable drug for treating Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative. Novartis said Signifor was the first drug to be approved in the United States that addresses the disease's underlying mechanism.

November 8, 2012
FDA panel recommends approval for Novartis Cushing's disease drug

A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.

EAST HANOVER, N.J. — A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.